Advanced Search

Home > Journals > Minerva Oftalmologica > Past Issues > Minerva Oftalmologica 2003 September-December;45(3-4) > Minerva Oftalmologica 2003 September-December;45(3-4):47-56

ISSUES AND ARTICLES   MOST READ   eTOC

CURRENT ISSUEMINERVA OFTALMOLOGICA

A Journal on Ophthalmology

Frequency: Quarterly

ISSN 0026-4903

 

Minerva Oftalmologica 2003 September-December;45(3-4):47-56

    REVIEWS

Glaucoma therapy: the cannabinoids way

Rossi S., Rinaldi M., Romano M., Rinaldi B., D'Amico M., Di Filippo C.

The newly discovered cannabinoids and their endogenous ligand arachidonylethanolamide opened the way to the use of the cannabinoids in medicine, particularly in the glaucoma therapy. Actually, the focus is posed on drugs predominately acting on specific CB1 receptors. These drugs seem to be able to reduce the 1st symp-tom of glaucoma, the ocular hypertension. New technologies such as microemulsion and cyclodextrins based pharmaceutical preparations enable these drugs to topical ophthalmic administration. This would minimize drug concentration in the systemic circulation and possible consequent adverse-side effects (hypotension, tachycardia and psychic disorders).

language: Italian


FULL TEXT  REPRINTS

top of page